GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs

Y. M. PETERSEN,1 D. G. BURRIN,2 AND P. T. SANGILD1
1Division of Animal Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark; and 2US Department of Agriculture/Agricultural Research Service Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030

Received 8 February 2001; accepted in final form 14 August 2001

Petersen, Y. M., D. G. Burrin, and P. T. Sangild. GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs. Am J Physiol Regulatory Integrative Comp Physiol 281: R1986–R1993, 2001.—Glucagon-like peptide-2 (GLP-2) is a potent intestinotropic factor in neonatal and adult animals. However, the GLP-2 responsiveness of the fetal intestine has not been established. To determine how stage of development affects the responsiveness to GLP-2, we examined GLP-2 receptor (GLP-2R) expression, gut morphology, and brush-border enzyme mRNA and activities in late-gestation fetal (n = 7) and parenterally fed neonatal (n = 7) piglets given GLP-2 (12.5 nmol/kg) twice daily for 6 days. The GLP-2R was expressed in the fetal and neonatal gastrointestinal tract. The biologically active GLP-2-(1–33) was undetectable (<5 pmol/l) in plasma of 98-day-gestation fetuses but increased significantly toward full term (115 days, 11 ± 1 pmol/l) and in neonates fed by total parenteral nutrition (23 ± 5 pmol/l). Exogenous GLP-2 had no effect on gut growth in fetuses but increased intestinal weight and villus height in neonates (P < 0.05). Crypt cell proliferation and the enzymes sucrase-isomaltase, lactase-phlorizin hydrolase, aminopeptidase A, and dipeptidyl peptidase IV were unchanged by GLP-2 in both groups. Aminopeptidase N mRNA and activity were increased in fetuses, while maltase mRNA and activity were increased in neonates. In conclusion, exogenous GLP-2 had different effects on small intestine growth and function in fetuses and neonates. This may be related to the normal developmental changes in intestine growth and function and to a maturation of the GLP-2R signaling pathways around the time of birth.

The pig small intestine undergoes tremendous growth and functional changes in the immediate pre- and postnatal periods. In the final 20% of gestation, the mucosal mass (relative to body weight) increases by ~150% and is associated with significant increases in the tissue-specific activities of the brush-border enzymes (15, 17). After birth, rapid small intestine growth and maturation are maintained in response to enteral food intake (2, 16). The regulatory factors involved in small intestine growth in the perinatal period remain relatively poorly understood, although local and systemic agents are known to play a role.

Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide released from the posttranslational processing of proglucagon in the enteroendocrine “L” cells of the small and large intestine. GLP-2 is secreted as a 33-amino acid peptide but is rapidly degraded at the NH2 terminus to inactive GLP-2-(3–33), in large part by dipeptidyl peptidase IV (DPP-IV) (8). Intestinal GLP-2 secretion is stimulated by enteral nutrient intake, and, accordingly, piglets administered total parenteral nutrition (TPN) have markedly decreased circulating GLP-2 concentrations (2, 13). The proglucagon mRNA is expressed in the fetal rat intestine (13), and we have shown that enteral nutrition stimulates GLP-2 secretion in premature newborn piglets (3). GLP-2 significantly stimulates epithelial cell proliferation, leading to increases in small intestine mucosal mass, colon mass, villus height, and crypt depth, and reverses the gut atrophy associated with TPN feeding (3, 6, 10, 12, 19). In addition to growth-related effects, GLP-2 has also been shown to affect the regulation of gastric emptying and intestinal absorption (1, 10, 23).

The actions of GLP-2 are mediated via a specific receptor belonging to the glucagon-secretin G protein-coupled receptor superfamily (14). The GLP-2 receptor (GLP-2R) mRNA has recently been identified in the small intestine of fetal and postnatal rats (13). This report, together with our earlier evidence showing that GLP-2 stimulates small intestine growth in the premature neonatal pig (3), suggests that the small intestine is responsive to GLP-2 early in development. Despite the evidence that proglucagon and GLP-2R mRNA are expressed in the fetus, there is no evidence as to whether the biologically active form of GLP-2 is present in the fetal circulation or whether, indeed, the fetal intestine is responsive to GLP-2. In the present study, we sought to determine whether the fetal intestine was responsive to exogenous GLP-2. Having established that premature newborn piglets are responsive to GLP-2 (3), we compared the effects of GLP-2 in fetuses with those in TPN-fed piglets delivered at full...
term. The specific objectives of the study were to compare fetal and neonatal pigs with respect to 1) the sites of GLP-2R expression and the concentrations of GLP-2 in the circulation, 2) the effects of GLP-2 on gut morphology and crypt cell proliferation, and 3) the effects of GLP-2 on lactase-phloridzin hydrolase (LPH), maltase-glucosylase (MGA), sucrase-isomaltase (SI), aminopeptidase N (ApN), aminopeptidase A (ApA), and DPP IV mRNA levels and enzyme activities.

METHODS

Fetal animals. Six pregnant sows (Large White × Landrace) of known gestational age (98 ± 2 days, full term = 115 ± 2 days) were sedated (azeperone, 0.05 ml/kg im; Janssen, Beerse, Belgium), and a superficial ear vein was catheterized under local anesthesia (lidocaine; Lignocaine, Willotox, Crawley, UK). General anesthesia was induced with thiopental sodium (5 mg/kg; Abbott Laboratories, North Chicago, IL) and isoflurane (1–2% in oxygen; Abbott Laboratories) using an endotracheal tube. The sow was covered with insulating blankets to prevent anesthesia-induced hypothermia, and great care was taken to maintain aseptic conditions around the ventral flank incision. A small incision (5 cm) was made in a relatively nonvascular area of the uterus, and the fetal allantoic and amniotic membranes were then carefully anchored onto the uterine wall incision. The head of a fetus was exteriorized and covered with a wet heating pad to prevent dehydration and cooling. A ventral midline incision was made in the fetal neck, and surrounding tissue was gently separated to expose the carotid artery. A polyvinyl catheter was inserted into the carotid artery and secured with sutures. The fetal skin, fetal membranes, and uterine incision were sutured separately. Antibiotics (50 mg ampicillin; Penbitrin, Beecham Laboratories) were administered to each operated fetus by injection into the amniotic cavity. With the use of this procedure, two more fetuses were randomly selected and catheterized. The duration of surgery was ~3 h. Antibiotics were given to the sow for 4 days (20 ml/day im; Streptocillin, Boeringer Ingelheim, Copenhagen, Denmark) after surgery, and progesterone was administered (50 mg/days im) 3 days after surgery as a precaution against preterm labor. Preliminary observations showed that GLP-2 infused into operated pig fetuses could pass into the maternal circulation. Therefore, to prevent possible cross-contamination of the control fetuses with GLP-2 via the placental circulation, all three catheterized fetuses from each sow were assigned to be vehicle-infused controls or GLP-2 infused. Fetal well-being was assessed daily by blood gas analyses (pH, Po2, Pco2) using a blood gas analyzer (NOVA Biomedical, Waltham, MA). Of the 18 operated fetuses, 5 died before completion of the study.

Full-term neonatal animals. A total of 14 cross-bred pigs (Large White × Landrace) were obtained by cesarean section after surgery, and progesterone was administered (50 mg/days im) 3 days after surgery as a precaution against preterm labor. Preliminary observations showed that GLP-2 infused into operated pig fetuses could pass into the maternal circulation. Therefore, to prevent possible cross-contamination of the control fetuses with GLP-2 via the placental circulation, all three catheterized fetuses from each sow were assigned to be vehicle-infused controls or GLP-2 infused. Fetal well-being was assessed daily by blood gas analyses (pH, Po2, Pco2) using a blood gas analyzer (NOVA Biomedical, Waltham, MA). Of the 18 operated fetuses, 5 died before completion of the study.

AJP-Regulatory Integrative Comp Physiol • VOL 281 • DECEMBER 2001 • www.ajpregu.org
neonatal pigs were infused with an intravenous bolus of BrdU (50 mg/kg; Sigma Aldrich) 4 h before they were killed. Sections (5 μm) fixed in Carnoy’s fluid were incubated with a mouse anti-BrdU/nuclease (Amersham Pharmacia Biotech, Piscataway, NJ) and then with biotinylated universal secondary antibody (anti-mouse IgG2a; The Binding Site). BrdU-labeled cells were visualized using 3,3′-diaminobenzidine substrate kit for peroxidase (Vector Laboratories, Burlingame, CA), and then slides were counterstained with 0.1% hematoxylin. The number of nuclei stained brown by BrdU in 10 vertically well-oriented crypts per hour of BrdU infusion was determined and expressed as a percentage of the total number of nuclei per crypt.

**RNA extraction.** Total RNA was extracted from individually frozen samples of fundus, proximal and distal small intestine, colon, and kidney collected from each pig (4). The RNA was then dissolved in 0.1% diethylpyrocarbonate (DEPC)-treated water, and recovery (absorbance at 260 nm) was determined and expressed as a percentage of the total absorbance at 260 nm to absorbance at 280 nm) were determined with an ultraviolet spectrophotometer (GeneQuant pro, Amersham Pharmacia Biotech, Cambridge, UK).

**Reverse transcription-polymerase chain reaction.** Individual samples of total RNA (3 μg), random decamer primers (50 μM; Ambion, Austin, TX), dNTP mix (10 mM each dGTP, dATP, dCTP, and dTTP; Life Technologies), and DEPC-treated water, and recovery (absorbance at 260 nm) and purity (ratio of absorbance at 260 nm to absorbance at 280 nm) were determined with an ultraviolet spectrophotometer (GeneQuant pro, Amersham Pharmacia Biotech, Cambridge, UK).

<table>
<thead>
<tr>
<th>Oligonucleotides</th>
<th>Annealing Temperatures and Cycles</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLP-2 VR</td>
<td>34°C, 31 cycles</td>
<td>5′-ACCTTGACGTGATGACAGC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-GTGGTCGCTCAGGTGACAGC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-AGCAGTGAAGTGAAGTGAAGACAGC-3′</td>
</tr>
<tr>
<td>LPH</td>
<td>51°C, 32 and 29 cycles</td>
<td>5′-CTCAGGTGACAGTCTGACCTCC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-AGCATGAAGTGAAGTGAAGACAGC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-CAGAAAGCTCCAGAAGTCTTAC-3′</td>
</tr>
<tr>
<td>MGA</td>
<td>56°C, 32 and 27 cycles</td>
<td>5′-AGAAACTCTTGCGCACATCCC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-TGGGACATCCGCTTGGTTGAC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-CAGGACATCCGCTTGGTTGAC-3′</td>
</tr>
<tr>
<td>SI</td>
<td>56°C, 33 and 29 cycles</td>
<td>5′-TCAGGGTGACAGTCTTAC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-AGCATGAAGTGAAGTGAAGACAGC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-CAGAAAGCTCCAGAAGTCTTAC-3′</td>
</tr>
<tr>
<td>ApN</td>
<td>58°C, 29 and 27 cycles</td>
<td>5′-ACATGACCTCTCACCACCTTACC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-GCAATCAGTCCAGTCAAGTGAC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-GTCCTTACGCAGTACAGTGAC-3′</td>
</tr>
<tr>
<td>ApA</td>
<td>56°C, 29 and 26 cycles</td>
<td>5′-CTTCGAGTACTCCAGTACAGTGAC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-GTCCTTACGCAGTACAGTGAC-3′</td>
</tr>
<tr>
<td>Antisense</td>
<td></td>
<td>5′-CAGAATCGTCCAGTACAGTGAC-3′</td>
</tr>
<tr>
<td>DPP IV</td>
<td>59°C, 28 and 27 cycles</td>
<td>5′-CCCTCGGGCCTTCGTGTTAC-3′</td>
</tr>
<tr>
<td>Sense</td>
<td></td>
<td>5′-TGAGATCGCGTCTCAGTACAGTGAC-3′</td>
</tr>
</tbody>
</table>

GLP-2R glucagon-like peptide-2 receptor; LPH, lactase-phloridzin hydrolase; MGA, maltase-glucoamylase; SI, sucrase-isomaltase; ApN and ApA, aminopeptidase N and A; DPP IV, dipeptidylpeptidase IV.

**PCR amplification of GLP-2R cDNA (fundus, proximal and distal small intestine, colon, and kidney) and brush-border enzyme cDNA (proximal and distal small intestine) was performed on individual samples. Three microliters of the cDNA from the reverse transcription reaction were added to 17 μl of a PCR master mix consisting of 10× PCR buffer minus Mg [200 mM Tris·HCl (pH 8.4), 500 mM KCl; Life Technologies], 10 mM dNTP mix, 50 mM MgCl2 (Life Technologies), autoclaved distilled water and 1 U of Taq DNA polymerase (Life Technologies), 1 μl of 18S rRNA internal standards (Ambion, Austin, TX), and specific sense and antisense oligonucleotides at 0.5 μM each (Table 1; TAG, Copenhagen, Denmark). The samples were denatured in a thermal cycler (model PTC-100, MJ Research, Cambridge, MA) at 95°C for 2 min and underwent amplification cycles with denaturation at 95°C for 1 min, annealing for 30 s at 51–59°C, and extension for 1 min at 72°C. An additional extension at 72°C for 10 min was performed, and the samples were then cooled to 4°C. To control for the absence of genomic DNA contamination, PCRs were carried out on samples in which the reverse transcriptase enzyme had been excluded in the reverse transcription reaction. Amplification products were electrophoresed on a 1% agarose gel (BDH Laboratory, Poole, UK) in Tris-borate-EDTA buffer and visualized by staining with 0.15% ethidium bromide.

To compare enzyme mRNA levels after GLP-2 treatment, we first determined the optimal annealing temperature for each primer set (Table 1) and then the range of PCR cycles over which the amplification efficiency of the reaction was at its maximum (for the specific primer set and the 18S rRNA standards) and remained constant using a pooled sample of proximal or distal cDNA from fetuses or neonates. A number of cycles within the linear range of amplification of each primer set were selected, and the PCRs were performed on individual samples for comparison. The relative abundance of the enzyme PCR products on the gels was quantified by an optical densitometry reading (Image Pro Plus 4.1 software) of PCR bands on digitalized pictures (BioCapt 97 software, Vilber Lourmat, Cedex, France) of gels. For each of the two age groups (fetuses and neonates), individual enzyme mRNA
was run on the same gel for all the pigs. The density of each enzyme cDNA band was expressed relative to the density of its corresponding 18S rRNA band. To confirm the identity of each PCR product, the cDNA was extracted from the gel (QIAquick gel extraction kit, West Sussex, UK), sequenced (TAG, Copenhagen, Denmark), and entered into BLAST (National Center for Biotechnology Information).

**Primers.** Oligonucleotides to recognize the pig GLP-2R were designed from regions of high homology between the GLP-2R cDNA sequences in rat (accession number AF105368) and human (AF105367). The sense and antisense oligonucleotides corresponded to nucleotides 529–548 and 964–983, respectively, in rat and human. Oligonucleotides were designed to identify MGA (491 bp; NM_004668), ApN (459 bp; Z29522), ApA (554 bp; U66371), and DPP IV (587 bp; X73277). Oligonucleotides to recognize pig LPH were designed from regions of high homology among LPH cDNA sequences from human (NM_002299), rat (X56747), and rabbit (Z27167) LPH. Oligonucleotides to recognize pig SI were designed from regions of high homology between SI cDNA sequences from human (NM_001041) and rat (NM_013061). The oligonucleotides recognized a 540- and a 484-bp product for LPH and SI, respectively. In the neonate pig gut, disaccharidase activities tend to be highest in the proximal intestine and peptidase activities highest in the distal region (17). On the basis of this observation, the relative abundance of disaccharidase mRNA was determined solely in the proximal segment, and that of peptidase mRNA was determined in the distal segment.

**Enzyme activity assays.** Enzyme activities were determined as previously described (17). Briefly, frozen intestinal tissue was homogenized in 1% Triton X-100 (6 ml/g tissue), and the homogenates were assayed for disaccharidase and peptidase activities. Sucrose (0.01 M; catalog no. 194018, Sigma) dissolved in 50 mM sodium maleate buffer (pH 6.0) was used to measure maltase activity, which represents the combined activity of MGA (EC 3.2.1.20) and L-5885, Sigma) was used to measure maltase activity, which represents the combined activity of MGA (EC 3.2.1.20) and L-5885, Sigma) dissolved in 50 mM sodium maleate buffer (pH 6.0). The GLP-2R transcript was expressed in fetal and neonatal pigs (Fig. 1). The density ratio of GLP-2R mRNA to 18S rRNA was significantly increased in the proximal small intestine of neonates compared with fetuses (5.0 ± 0.6 vs. 2.0 ± 0.2) and was unchanged in the fundus (0.72 ± 0.13 vs. 0.67 ± 0.04), distal intestine (2.4 ± 0.6 vs. 1.6 ± 0.6), and colon (3.7 ± 0.6 vs. 3.1 ± 0.3). GLP-2R mRNA was not present at detectable levels in fetal and neonatal kidney (Fig. 1).

**Body weights and gut growth.** In fetuses, body weights at delivery did not differ among the groups of unoperated, GLP-2-infused, and vehicle-infused control animals (1,193 ± 35, 1,168 ± 53, and 1,207 ± 46 g, respectively). Fetal GLP-2 infusion had no effect on small intestine weight (Fig. 2), proportion of dry mucosa (73 ± 1 vs. 72 ± 2%), and colon weight (Fig. 2). Similarly, GLP-2 had no effect on small intestine villus height (Fig. 3A), crypt depth or muscularis thickness, and rates of cell proliferation (Fig. 3B). Cell proliferation rates were, however, significantly higher in the proximal than in the distal intestine (P < 0.05).

In neonates, body weights and daily weight gain were not different between those treated with GLP-2 (GLP-2 and vehicle infusion), sow, intestinal region (proximal, middle, and distal), and treatment × region as fixed effects (18). For the fetuses, values from unoperated pigs were included in the model to allow correction for sow (litter effects). The results are expressed as the adjusted least-squares means ± SE or means ± SE, and differences between two means were tested by the least significant difference test or Student’s t-test. P = 0.05 was used as the critical level of significance for all statistical evaluations.

**RESULTS**

Circulating GLP-2 and tissue GLP-2R. At 98 ± 2 days of gestation (the time of fetal surgery), mean plasma GLP-2 levels were below the limit of detection (<5 pM), but the values increased significantly in the prenatal period to 11 ± 1 (SE) pM at full term (P < 0.05). Across the days of the experiment (GLP-2 or vehicle infusions), the basal GLP-2 levels were significantly higher in both groups of GLP-2-infused pigs (252 ± 98 and 309 ± 120 pM in fetuses and neonates, respectively) than in their corresponding controls (14 ± 2 and 23 ± 5 pM, respectively).

The partial pig GLP-2R cDNA sequenced showed 86% and 84% similarity to human and rat GLP-2R. The GLP-2R transcript was expressed in fetal and neonatal pigs (Fig. 1). The density ratio of GLP-2R mRNA to 18S rRNA was significantly increased in the proximal small intestine of neonates compared with fetuses (5.0 ± 0.6 vs. 2.0 ± 0.2) and was unchanged in the fundus (0.72 ± 0.13 vs. 0.67 ± 0.04), distal intestine (2.4 ± 0.6 vs. 1.6 ± 0.6), and colon (3.7 ± 0.6 vs. 3.1 ± 0.3). GLP-2R mRNA was not present at detectable levels in fetal and neonatal kidney (Fig. 1).
and controls (1,651 ± 38 vs. 1,641 ± 30 g and 52 ± 5 vs. 44 ± 2 g/day, respectively). GLP-2 significantly increased small intestine weight (Fig. 2), proportion of dry mucosa (70 ± 1 vs. 63 ± 1%), and colon weight (Fig. 2). In the proximal and distal small intestine, GLP-2 infusion significantly increased villi height (Fig. 3A), with no effects on crypt depth and muscle thickness. GLP-2 had no effect on the rates of crypt cell proliferation (Fig. 3B), and the rates did not differ between the proximal and distal intestine.

Disaccharidase and peptidase mRNA levels and activities. In fetuses, GLP-2 significantly increased ApN mRNA levels and activity in the distal small intestine but had no effect on other enzymes in the proximal intestine (LPH, MGA, and SI) and distal intestine (ApA and DPP IV; Figs. 4–6). In neonatal pigs, GLP-2 significantly increased MGA mRNA levels and maltase activity in the proximal small intestine but had no effect on other enzymes in the proximal intestine (LPH and SI) and distal intestine (ApN, ApA, and DPP IV; Figs. 4–6).

DISCUSSION

The main goal of this study was to determine whether the fetal intestine is responsive to exogenous GLP-2. Given evidence that GLP-2 is a potent gut trophic factor, our end points were measures of intestinal growth and function. We have shown that the GLP-2R is expressed in the gastrointestinal tract of pig fetuses and neonates, consistent with earlier studies in adult rats (14, 24). In newborn pigs, exogenous GLP-2 induced a marked increase in intestinal mucosal mass and villus height. Because the pigs were maintained on TPN, this effect occurred in the absence of luminal...
nutrient stimuli. The trophic action of GLP-2 may be mediated via an inhibition of mucosal proteolysis and apoptosis, as shown in our previous study on premature TPN-fed pigs (3). GLP-2 had no effect on cell proliferation in premature pigs (3) or in fetal and full-term newborn pigs (present study), even though an increase in cell proliferation has previously been reported in studies on adult rodents (6). It has been uncertain whether the trophic actions of GLP-2 are mediated directly via receptors expressed on enterocytes. Recent studies identifying the receptor protein solely on the enteroendocrine cells have led to the speculation that the trophic effects of GLP-2 are probably mediated indirectly via peptidergic mediators (24). Thus our results suggest that some component of this putative paracrine receptor signaling mechanism is absent or not fully developed in the period around birth.

Endogenous GLP-2 secretion from intestinal L cells is primarily regulated by enteral nutrient intake (2). Circulating GLP-2 is undetectable in the fetus before birth, suggesting that the luminal contents (amnion and meconium) to which the fetus is exposed in utero do not play a major role in regulating GLP-2 secretion. In contrast to the effects of GLP-2 in neonates, we show that GLP-2 infusion had no effect on mucosal growth and villus height in the fetuses. The absence of a trophic effect of GLP-2 in the fetal gut raises several possibilities. First, the fetal GLP-2R may not be functionally coupled to the secondary pathways (e.g., cAMP, phosphatidylinositide 3-kinase, and mitogen-activated protein kinases) that are known to mediate changes in epithelial cell proliferation (9, 14). Second, it is possible that the fetal GLP-2R is indeed functional but that the enteral stimulus of swallowed amniotic fluid is sufficient to render the intestinal mucosa in-
sensitive to the trophic effects of pharmacological plasma GLP-2 concentrations. However, this still implies that the fetal intestine is less responsive to GLP-2, because previous studies in rodents have shown that exogenous GLP-2 treatment markedly stimulates intestine growth, even when animals are fed enterally (6, 12).

A secondary end point we used to assess GLP-2 responsiveness was intestinal digestive function, based on the expression and activity of several intestinal disaccharidases and peptidases. There are few studies in the literature focusing on the effect of GLP-2 on the expression and activity of brush-border enzymes. GLP-2 increases SI expression in the rat ileum (11) but has no effect on maltase, SI, LPH, and DPP IV activities in mouse duodenum (1). In the present study, disaccharidase and peptidase expression have been measured in the proximal and distal small intestine, respectively, to provide a more complete overview of the effects of GLP-2 on enzyme regulation in the small intestine. In the fetuses, GLP-2 administration selectively increased ApN mRNA levels and activity, whereas in the neonates, GLP-2 had a significant stimulatory effect only on maltase mRNA levels and activity. The increase in ApN and maltase mRNA levels, together with increased activity, suggests that GLP-2 regulates the function of these enzymes at the level of transcription and that the intestine of fetal and neonatal pigs is responsive to GLP-2 treatment. The effects of GLP-2 on the fetal intestine did not, however, reflect the changes in enzyme activities normally occurring in the perinatal period. Therefore, our findings suggest that GLP-2 has a limited role in the normal maturation of small intestine growth and function at this time. Furthermore, the changes in intestine growth and function in GLP-2-infused fetal and neonatal piglets do not necessarily indicate that GLP-2 is involved in the normal regulation of gut physiology, inasmuch as pharmacological concentrations of circulating GLP-2 were present in the circulation of these animals.

We were unable to detect the active GLP-2 in plasma from 98-day fetuses (<5 pM), but there were measurable amounts in the 105-day fetus, and the levels increased further into the postnatal period of TPN-fed neonates (23 ± 5 pM). A recent study in rodents suggests that GLP-2 is present in tissue extracts and media derived from cultured fetal intestinal tissue (13). Moreover, the GLP-2 concentration in intestinal tissue increased during early postnatal development, whereas that in plasma decreased. Although we have not measured the peptide concentrations in intestinal tissue, using this NH2-terminal assay, we have measured GLP-2 in pig plasma from a range of ages, including the earliest detectable fetal age (i.e., 105 days of gestation) in the present study and in young pigs at 14–30 days of age (2, 3, 22). Across this age range, the basal circulating GLP-2 concentration in pigs that were fasted or fed exclusively via the parenteral route ranged from 14 pM in fetuses to as high as 30 pM at 30 days of age. Similarly, the GLP-2 concentrations in pigs that were enterally fed sow’s milk or a cow’s milk formula ranged from ~50 pM in premature newborn pigs to as high as 100 pM in 30-day-old pigs. Taken together, these observations suggest that, in the pig at least, the circulating concentration, and perhaps secretion, of GLP-2 increases during early postnatal development. Changes in the secretion of GLP-2 can be due to a number of factors, such as the presence of the proconvertase enzymes involved in the specific processing of proglucagon to yield GLP-2; however, the ontogeny of the proconvertase enzymes has not been studied in the pig. Although it is certain that enteral nutrition is a major stimulus for intestinal GLP-2 secretion, it will be of interest to establish whether it results from merely an increase in the basal concentration or whether intestinal GLP-2 secretion becomes more responsive to enteral nutrition with advancing age.

In conclusion, we have shown that the GLP-2R mRNA is expressed in the gastrointestinal tissues of the fetal and neonatal pig and that the signaling pathways involved in the trophic responses of the small intestine to GLP-2 are stimulated by birth and/or gut maturation. In addition, the stimulatory effect of exogenous GLP-2 on maltase and ApN function in fetal and neonatal piglets suggests that the stage of small intestine development affects the responsiveness to GLP-2.

Perspectives

A better understanding of the factors involved in regulating small intestine growth is crucial in the design of treatments aimed at improving small intestine function. In this study, we have shown that the small intestine was responsive to GLP-2 and that the extent of this responsiveness was associated with gut maturity. This early responsiveness of the small intestine suggests that GLP-2 could potentially be used to enhance small intestine growth or function in neonates maintained on TPN. Before such clinical trials can be performed, however, further studies are needed to determine the developmental profile (localization and distribution) of the GLP-2R protein and the mechanisms (direct or indirect) by which the actions of GLP-2 are mediated.

We gratefully acknowledge the contribution of Bollette Hartmann and Jens J. Holst in the running of the GLP-2 radioimmunoassays. We thank Mette Schmidt, Jan Elnif, and Randy Buddington for assistance and valuable discussions and Ebba de Neergaard-Harrison, Anna Siekierska, Inger Heinze, Bente Synnesvedt, Anne Pedersen, and Xiaoyan Chang for skilled technical assistance. Susanne Gerlac and the Department of Pharmacy at Rigshospitalet (Copenhagen) are gratefully acknowledged for help in the preparation of the TPN solutions.

This work was supported by Danish Agricultural and Veterinary Research Council Program 9702803, a Ph.D. student scholarship from the Danish Royal Veterinary and Agricultural University, and a travel grant from Nortoft Thomsen Legat.

REFERENCES

1. Brubaker PL, Izzo A, Hill M, and Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-